Table 5.

Results of the mixed models’ intention to treat analyses serum concentrations 6 months after the start of the intervention (T1)

Outcome	Intervention group N = 64	Control group N = 30	Model A N = 94			Model B N = 87
Serum concentrations	Mean (sd)	Mean (sd)	B (95% CI)	P value	d	B (95% CI)	P value	d
IGF-I
Baseline	13.71 (4.48)	14.16 (4.37)
6 months	14.58 (4.97)	14.47 (4.15)	0.23 (− 0.27 to 0.74)	.36	.05	0.21 (− 0.33 to 0.76)	.45	.05
Insulin
Baseline	49.91 (33.74)	54.62 (37.49)
6 months	43.55 (36.30)	46.18 (21.79)	0.88 (− 3.50 to 5.26)	.69	.03	1.44 (− 3.29 to 6.20)	.55	.04
Total cholesterol
Baseline	5.34 (1.17)	5.29 (1.11)
6 months	5.40 (1.17)	5.33 (1.02)	0.02 (− 0.08 to 0.12)	.70	.02	0.02 (− 0.09 to 0.13)	.69	.02
HDL-cholesterol
Baseline	1.43 (0.44)	1.43 (0.36)
6 months	1.45 (0.45)	1.48 (0.36)	− 0.01 (− 0.05 to 0.02)	.46	.02	− 0.01 (− 0.05 to 0.03)	.62	.02
Triglycerides
Baseline	1.52 (1.04)	1.62 (0.94)
6 months	1.51 (0.88)	1.55 (0.85)	0.02 (− 0.08 to 0.12)	.67	.02	0.02 (− 0.09 to 0.13)	.68	.02

Model A: adjusted for y at baseline, age, and sex. Model B: adjusted for y at baseline, age, sex, education, and ApoE-ε4 carrier status. PA Physical activity as measured in daily number of steps taken, ADL Activities of daily living, IGF-I Insulin-like growth factor 1, HDL High-density lipoprotein, d Cohen’s d